Recent Updates
Recently added Catalysts

REGN21353

Phase 1/2

Metastatic Castration-Resistant Prostate Cancer | Small Molecules | Oncology |Regeneron Pharmaceuticals, Inc.|Trials Updated: Sep 30, 2026

REGN21353 development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Sep 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment192

FDA Designations

No designations recorded

REGN21353 clinical trials

REGN21353 · 1 trial · 2 indications

Phase 1/2 1
NCT07850921REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult ParticipantsMetastatic Castration-Resistant Prostate Cancer
NOT YET_RECRUITING192 Analytics
PHASE1/PHASE2NOT YET_RECRUITING
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
Metastatic Castration-Resistant Prostate CancerUnlock trial analytics

Study Endpoints

Primary Endpoints

Occurrence of Treatment Emergent Adverse Events (TEAEs)
Up to 5 years

Dose escalation

Occurrence of Dose-Limiting Toxicities (DLTs)
Up to 42 days

Dose escalation

Occurrence of Serious Adverse Events (SAEs)
Up to 5 years

Dose escalation

Occurrence of Adverse Events of Special Interests (AESIs)
Up to 5 years

Dose escalation

Composite Response Rate (CRR) of ≥50% decline of prostate specific antigen (PSA) and/or confirmed radiographic response of complete response (CR) or partial response (PR)
Up to 5 years

Dose expansion

Secondary Endpoints

(CRR) of ≥50% decline of prostate specific antigen (PSA) and/or confirmed radiographic response of complete response (CR) or partial response (PR)
Up to 5 years
Occurrence of TEAEs
Up to 5 years
Occurrence of SAEs
Up to 5 years
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Module 1: monotherapyEXPERIMENTAL -
Module 2: combinationEXPERIMENTAL -

Interventions

NameTypeDescription
REGN21353DRUGAdministered per the protocol
NezastomigDRUGAdministered per the protocol
Sarilumab Prophylaxis (Contingency)DRUGMay be administered as pretreatment, per the protocol
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexMALE
Healthy VolunteersNo

Key Inclusion Criteria: 1. Is male with histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma 2. Has metastatic castration-resistant prostate cancer with prostate-specific antigen value as described in the protocol and that has progressed within ...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWSep 30, 2026NCT07850921NEW_TRIAL: changed
LOWSep 30, 2026NCT07850921NEW_TRIAL: changed

Frequently asked questions about REGN21353

What is REGN21353?

REGN21353 is an investigational small molecule developed by Regeneron Pharmaceuticals, Inc. for metastatic castration-resistant prostate cancer (mCRPC). It is in Phase 1 clinical development and is being studied both as a single agent and in combination with nezastomig in adult male participants.

What is REGN21353 used for?

REGN21353 is being developed for the treatment of metastatic castration-resistant prostate cancer, also called mCRPC. This is an advanced form of prostate cancer that has spread beyond the prostate and no longer responds to androgen deprivation therapy. The drug remains investigational and has not been approved for any use.

Who makes REGN21353?

REGN21353 is developed by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker REGN. Regeneron is the sponsor of the clinical program evaluating the small molecule in metastatic castration-resistant prostate cancer.

What phase is REGN21353 in?

REGN21353 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The Phase 1 program is evaluating the drug in adult male participants with metastatic castration-resistant prostate cancer.

What clinical trials is REGN21353 in?

REGN21353 is being evaluated in one Phase 1 trial, NCT07850921, titled REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants. The study is not yet recruiting, is controlled, and plans to enroll 192 participants aged 18 years and older.

Is REGN21353 combined with other drugs in its trial?

Yes. The Phase 1 trial NCT07850921 evaluates REGN21353 both as a single agent and in combination with nezastomig in adults with metastatic castration-resistant prostate cancer. The study is controlled and is not yet recruiting, with a planned enrollment of 192 male participants.